BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

UCB buying Engage for $125M  UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler combo in Phase II testing for the rapid termination of epileptic seizures. Engage will receive $125 million...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for...
BioCentury | May 13, 2020
Product Development

May 12 Quick Takes: Skyhawk, Merck expand deal; plus Sanofi’s Sarclisa and clinical updates drive gains for Gamida, CymaBay

Autoimmune, metabolic diseases added to Skyhawk-Merck deal  Skyhawk Therapeutics Inc. expanded a collaboration with Merck & Co. Inc. (NYSE:MRK) to discover and develop small molecules that modulate RNA splicing for autoimmune and metabolic diseases; the...
BioCentury | May 1, 2020
Regulation

As first subcutaneous anti-CD38 mAb, Darzalex Faspro secures J&J’s lead in MM, shaves hours off infusion time

FDA’s approval of a subcutaneous form of Darzalex secures J&J’s leading position in the anti-CD38 market just two months after a new entrant threatened to cut into its market share. It’s also a game changer...
BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

Karyopharm gained $11.38 (70%) to $27.72 on Monday, adding about $746 million in market value, after announcing that Xpovio selinexor met the primary endpoint of improving PFS in the confirmatory Phase III BOSTON trial to...
BioCentury | Mar 3, 2020
Regulation

Sanofi sees first fruit of renewed oncology commitment with Sarclisa approval

Sarclisa isatuximab will be the first oncology drug Sanofi launches in more than a decade, its approval Monday marking the pharma’s first cancer win after its re-entry into the space. The company’s next step is...
BC Extra | Jan 22, 2020
Company News

Jan. 21 Company Quick Takes: First BCMA-targeted therapy gets Priority Review from FDA; plus Roche-Seattle Genetics, AZ-Merck, Chi-Med

Priority Review for GSK's anti-BCMA therapy in MM  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA granted Priority Review to a BLA for belantamab mafodotin to treat fourth-line relapsed or refractory multiple myeloma in patients who have...
BC Extra | Dec 17, 2019
Clinical News

GSK looks to expand into MM subsets after submitting first anti-BCMA BLA

GSK is the first company out of the gate with a regulatory submission for a BCMA-targeted therapy. The ADC’s most recent response rates are lower than many programs from competing modalities against the same target...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
Items per page:
1 - 10 of 45